Compare ELME & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | QNCX |
|---|---|---|
| Founded | 1960 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 167.0M |
| IPO Year | 1994 | 2019 |
| Metric | ELME | QNCX |
|---|---|---|
| Price | $2.04 | $0.09 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $12.67 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 14.0M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 741.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $206,360,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.98 | $0.08 |
| 52 Week High | $17.68 | $4.55 |
| Indicator | ELME | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 23.19 | 29.77 |
| Support Level | $1.98 | $0.08 |
| Resistance Level | $2.26 | $0.98 |
| Average True Range (ATR) | 0.05 | 0.01 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 29.63 | 21.56 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.